NASDAQ:CORT Corcept Therapeutics (CORT) Stock Price, News & Analysis → How to Make 100X on the AI Boom (From InvestorPlace) (Ad) Free CORT Stock Alerts $27.53 +0.49 (+1.81%) (As of 05/13/2024 ET) Add Compare Share Share Today's Range$27.23▼$29.2750-Day Range$22.21▼$27.5352-Week Range$20.84▼$34.28Volume1.77 million shsAverage Volume1.36 million shsMarket Capitalization$2.87 billionP/E Ratio25.97Dividend YieldN/APrice Target$40.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Corcept Therapeutics alerts: Email Address Corcept Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.7% Upside$40.10 Price TargetShort InterestBearish22.07% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.44Based on 8 Articles This WeekInsider TradingSelling Shares$2.54 M Sold Last QuarterProj. Earnings Growth44.33%From $0.97 to $1.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsMedical Sector90th out of 2,771 stocksPharmaceutical Preparations Industry29th out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Corcept Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted22.07% of the float of Corcept Therapeutics has been sold short.Short Interest Ratio / Days to CoverCorcept Therapeutics has a short interest ratio ("days to cover") of 18, which indicates bearish sentiment.Change versus previous monthShort interest in Corcept Therapeutics has recently decreased by 6.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 70.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for cancer", and "Clinical research services for metabolic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -0.75. Previous Next 2.5 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Corcept Therapeutics this week, compared to 5 articles on an average week.Search Interest6 people have searched for CORT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,540,078.00 in company stock.Percentage Held by Insiders20.50% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.61% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corcept Therapeutics' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to grow by 44.33% in the coming year, from $0.97 to $1.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 25.97, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.05.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 25.97, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 183.67.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Corcept Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Tomorrow InvestorThe Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.Click here to see how to invest About Corcept Therapeutics Stock (NASDAQ:CORT)Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Read More CORT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CORT Stock News HeadlinesMay 14 at 5:18 AM | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $187,902.00 in StockMay 7, 2024 | insidertrades.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $281,580.00 in StockMay 14 at 5:20 AM | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 7,227 SharesMay 13 at 8:30 AM | finance.yahoo.com3 High Insider Ownership US Growth Companies With Earnings Growth Up To 70%May 7, 2024 | americanbankingnews.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Joseph Douglas Lyon Sells 10,830 SharesMay 6, 2024 | americanbankingnews.comTruist Financial Raises Corcept Therapeutics (NASDAQ:CORT) Price Target to $44.00May 6, 2024 | americanbankingnews.comCorcept Therapeutics (NASDAQ:CORT) Given New $40.00 Price Target at HC WainwrightMay 6, 2024 | americanbankingnews.comHC Wainwright Analysts Reduce Earnings Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT)May 5, 2024 | americanbankingnews.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 4.5%May 4, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Increased by HC WainwrightMay 3, 2024 | finance.yahoo.comCorcept Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 2, 2024 | gurufocus.comQ1 2024 Corcept Therapeutics Inc Earnings Call TranscriptMay 1, 2024 | investorplace.comCORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | sfgate.comCorcept: Q1 Earnings SnapshotMay 1, 2024 | finance.yahoo.comCorcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024May 1, 2024 | globenewswire.comCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateApril 29, 2024 | finance.yahoo.comCorcept Completes Enrollment in Phase 4 CATALYST TrialApril 24, 2024 | globenewswire.comCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallApril 23, 2024 | markets.businessinsider.comPromising Clinical Outcomes and Market Potential: Buy Rating for Corcept’s RelacorilantApril 22, 2024 | msn.comMid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This QuarterApril 22, 2024 | msn.comCorcept falls after phase 3 results on Cushing's candidate doesn't include some dataApril 22, 2024 | finance.yahoo.comCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s SyndromeApril 15, 2024 | finance.yahoo.comCorcept Therapeutics Incorporated (CORT)April 15, 2024 | finance.yahoo.comCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)April 12, 2024 | stocknews.com3 Promising Biotech Stocks Driving Weekly GainsSee More Headlines Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/13/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees352Year Founded1998Price Target and Rating Average Stock Price Target$40.10 High Stock Price Target$47.50 Low Stock Price Target$31.00 Potential Upside/Downside+45.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.06 Trailing P/E Ratio25.97 Forward P/E Ratio28.38 P/E GrowthN/ANet Income$106.14 million Net Margins22.38% Pretax Margin26.95% Return on Equity24.19% Return on Assets19.56% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.10 Sales & Book Value Annual Sales$482.38 million Price / Sales5.94 Cash Flow$0.98 per share Price / Cash Flow28.23 Book Value$4.92 per share Price / Book5.60Miscellaneous Outstanding Shares104,110,000Free Float82,769,000Market Cap$2.87 billion OptionableOptionable Beta0.50 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Joseph K. Belanoff M.D. (Age 67)Co-Founder, President, CEO & Director Comp: $2.43MMr. Atabak Mokari (Age 47)CFO & Treasurer Comp: $863.03kMr. Sean Maduck (Age 47)President of Endocrinology Comp: $1.05MDr. William Guyer Pharm.D. (Age 56)Chief Development Officer Comp: $1.03MMr. Gary Charles Robb (Age 61)Chief Business Officer & Secretary Comp: $1.08MMr. Joseph Douglas Lyon (Age 46)Chief Accounting & Technology Officer Dr. Hazel Hunt Ph.D. (Age 64)Chief Scientific Officer Comp: $895.16kMs. Amy FloodChief Human Resources & Communications OfficerMs. Monica Tellado (Age 51)President of Emerging Markets Mr. Roberto W. VieiraPresident of OncologyMore ExecutivesKey CompetitorsRa PharmaceuticalsNASDAQ:RARXSupernus PharmaceuticalsNASDAQ:SUPNTaro Pharmaceutical IndustriesNYSE:TAROXencorNASDAQ:XNCRAxsome TherapeuticsNASDAQ:AXSMView All CompetitorsInsiders & InstitutionsCANADA LIFE ASSURANCE CoSold 12,982 shares on 5/14/2024Ownership: 0.076%Clearbridge Investments LLCBought 582,355 shares on 5/13/2024Ownership: 0.559%HAP Trading LLCBought 50,000 shares on 5/13/2024Ownership: 0.000%UniSuper Management Pty LtdBought 17,536 shares on 5/13/2024Ownership: 0.017%O Shaughnessy Asset Management LLCBought 1,808 shares on 5/13/2024Ownership: 0.008%View All Insider TransactionsView All Institutional Transactions CORT Stock Analysis - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CORT shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 1 year price objectives for Corcept Therapeutics' shares. Their CORT share price targets range from $31.00 to $47.50. On average, they anticipate the company's share price to reach $40.10 in the next twelve months. This suggests a possible upside of 45.7% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2024? Corcept Therapeutics' stock was trading at $32.48 on January 1st, 2024. Since then, CORT shares have decreased by 15.2% and is now trading at $27.53. View the best growth stocks for 2024 here. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.04. The biotechnology company earned $146.80 million during the quarter, compared to analyst estimates of $141.19 million. Corcept Therapeutics had a net margin of 22.38% and a trailing twelve-month return on equity of 24.19%. Corcept Therapeutics's revenue was up 38.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 earnings per share. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO) and iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics updated its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $610.6 million. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.19%), Norden Group LLC (1.92%), Jupiter Asset Management Ltd. (0.72%), Clearbridge Investments LLC (0.56%), Principal Financial Group Inc. (0.51%) and Cambridge Investment Research Advisors Inc. (0.31%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CORT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportGuard Against the Coming Financial UpheavalPorter & CompanyDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThis 1 Biotech Stock has been shocking the marketsHuge AlertsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
